Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Carl R. who wrote (2211)	2/7/2000 7:26:00 PM
From: Street Walker	Read Replies (1) \| Respond to of 5582

* GUMM -- a value investment Earnings Growth superb: Just released 4Q earnings of 0.13 Read Dan's projection for Q1: Earnings of around 0.45 messages.yahoo.com They are preparing to launch Zicam Internationally so that would increase the sales/earnings considerably. GUMM's major product is Zicam, a nasal gel for the common cold. Reduces a 14 day cold to last only 3 days. Cost is under $10. They are bringing out another product, Nicotine Gum, in a joint venture with a Tobacco company which distributes to 140 countries. Read the news releases and comprehend the significance of Zicam in the $3 Billion US OTC cold market. You should start seeing ZICAM television commercials nationally. Regards, S.W.